The Investor
07 Mar 2026, 14:51
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis treatment
The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s oral drug Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
Sotyktu is the first tyrosine kinase 2 (TYK2) inhibitor approved for this condition. The approval was based on results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, where significantly more patients receiving once-daily Sotyktu achieved an ACR20 response at week 16 compared with placebo.
The drug was previously approved in 2022 for moderate-to-severe plaque psoriasis. Bristol Myers Squibb said the new indication expands treatment options for patients with psoriatic disease affecting both joints and skin.
Business Wire
The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s oral drug Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
Sotyktu is the first tyrosine kinase 2 (TYK2) inhibitor approved for this condition. The approval was based on results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, where significantly more patients receiving once-daily Sotyktu achieved an ACR20 response at week 16 compared with placebo.
The drug was previously approved in 2022 for moderate-to-severe plaque psoriasis. Bristol Myers Squibb said the new indication expands treatment options for patients with psoriatic disease affecting both joints and skin.
Business Wire